Cited by 1,258Polyomavirus and related diseasesCancer Immunotherapy and BiomarkersNonmelanoma Skin Cancer Studies

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

Open access

Nghiem, Paul T., Bhatia, Shailender, Lipson, Evan J., Kudchadkar, Ragini R., Miller, Natalie J., Annamalai, Lakshmanan, Berry, Sneha, Chartash, Elliot K., Daud, Adil, Fling, Steven P., Friedlander, Philip A., Kluger, Harriet M., Kohrt, Holbrook E., Lundgren, Lisa, Margolin, Kim, Mitchell, Alan, Olencki, Thomas, Pardoll, Drew M., Reddy, Sunil A., Shantha, Erica M., Sharfman, William H., Sharon, Elad, Shemanski, Lynn R., Shinohara, Michi M., Sunshine, Joel C., Taube, Janis M., Thompson, John A., Townson, Steven M., Yearley, Jennifer H., Topalian, Suzanne L., Cheever, Martin A.·2016·New England Journal of Medicine

DOI 10.1056/nejmoa1603702PMC PMC4927341

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Merkel-cell carcinoma is an aggressive skin cancer that is linked to exposure to ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell carcinoma often responds to chemotherapy, but responses are transient. Blocking the programmed death 1 (PD-1) immune inhibitory pathway is of interest, because these tumors often express PD-L1, and MCPyV-specific T cells express PD-1. METHODS: In this multicenter, phase 2, noncontrolled study, we assigned adults with advanced Merkel-cell carcinoma who had received no previous systemic therapy to receive pembrolizumab (anti-PD-1) at a dose of 2 mg per kilogram of body weight every 3 weeks. The primary end point was the objective response rate according to Response Evaluation Criteria in Solid Tumors, version 1.1. Efficacy was correlated with tumor viral status, as assessed by serologic and immunohistochemical testing. RESULTS: A total of 26 patients received at least one dose of pembrolizumab. The objective response rate among the 25 patients with at least one evaluation during treatment was 56% (95% confidence interval [CI], 35 to 76); 4 patients had a complete response, and 10 had a partial response. With a median follow-up of 33 weeks (range, 7 to 53), relapses occurred in 2 of the 14 patients who had had a response (14%). The response duration ranged from at least 2.2 months to at least 9.7 months. The rate of progression-free survival at 6 months was 67% (95% CI, 49 to 86). A total of 17 of the 26 patients (65%) had virus-positive tumors. The response rate was 62% among patients with MCPyV-positive tumors (10 of 16 patients) and 44% among those with virus-negative tumors (4 of 9 patients). Drug-related grade 3 or 4 adverse events occurred in 15% of the patients. CONCLUSIONS: In this study, first-line therapy with pembrolizumab in patients with advanced Merkel-cell carcinoma was associated with an objective response rate of 56%. Responses were observed in patients with virus-positive tumors and those with virus-negative tumors. (Funded by the National Cancer Institute and Merck; ClinicalTrials.gov number, NCT02267603.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1603702

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Self-citation
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citation
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citation
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447

Show all 42 references

Research works printed but not linked: 3

10.2307/2281868 · DOI · Paper page
Berger RL, 1996, Am Stat, 50, 314
Behr DS, 2014, Int J Clin Exp Pathol, 7, 7610

Sorted by citations

Items 901–1,000 of 1,000

Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US
Bharmal, M. F., Kearney, M., Zheng, Y., & Phatak, H. M. (2019) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s202642 · Cited by 4
Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoint Inhibitor-Based Immunotherapy
Hou, Q., & Xu, H. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_7 · Cited by 4
Merkelzellkarzinom
Drusio, C., Becker, J. C., Schadendorf, D., & Ugurel, S. (2019) · Der Hautarzt · doi:10.1007/s00105-019-4360-5 · Cited by 4
Advanced Merkel cell carcinoma—A focus on medical drug therapy
Wollina, U., Koch, A., & Cardoso, J. C. (2020) · Dermatologic Therapy · doi:10.1111/dth.13675 · Cited by 4
Spontaneous Regression and Complete Response to Immune Checkpoint Blockade in a Case of High-Grade Neuroendocrine Carcinoma
Raufi, A. G., May, M. S., Greendyk, R. A., Iuga, A. C., Ahmed, F., MANSUKHANI, M. M., & Manji, G. A. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00103 · Cited by 4
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge” (December 4th–5th, 2019, Naples, Italy)
Ascierto, P. A., Butterfield, L. H., Campbell, K., Daniele, B., Dougan, M. L., Emens, L. A., Formenti, S. C., Jankú, F., Khleif, S. N., Kirchhoff, T., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02627-y · Cited by 4
Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd–3rd, 2020, Italy)
Ascierto, P. A., Bifulco, C. B., Ciardiello, F., Demaria, S., Emens, L. A., Ferris, R. L., Formenti, S. C., Galon, J., Khleif, S. N., Kirchhoff, T., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02895-2 · Cited by 4
Self-citation
Patient Resources in a Cancer Center
Yassine, F., & Kharfan‐Dabaja, M. A. (2021) · Springer eBooks · doi:10.1007/978-3-030-82052-7_15 · Cited by 4
First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: Study protocol for a prospective, multicenter, phase II study
Li, X., Ma, Q., Chen, C., Li, H., & Cao, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.958905 · Cited by 4
Metastatic Merkel-cell carcinoma: the dawn of a new era
O'Brien, T. N., & Power, D. G. (2018) · BMJ Case Reports · doi:10.1136/bcr-2018-224924 · Cited by 4
Immune checkpoint inhibitor therapy in HIV-associated Merkel cell carcinoma: A case series of 3 patients
Park, S. Y., Church, C. D., Alexander, N. A., Shinohara, M. M., Paulson, K. G., Lewis, K. D., Lee, N. S., & Nghiem, P. (2020) · JAAD Case Reports · doi:10.1016/j.jdcr.2020.11.020 · Cited by 4
Self-citation
Management of regional metastatic disease in cutaneous malignancy of the head and neck. 3. Merkel cell carcinoma
Bowe, C. M., Gurney, B., Whitaker, S. J., & Newlands, C. (2019) · British Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.bjoms.2019.08.022 · Cited by 4
Letter to the Editor: Could Immunogenicity of Kaposi Sarcoma Be More Linked to Viral Antigens Than to the Tumor Mutational Burden?
Delyon, J., Arangalage, D., Baroudjian, B., & Lebbé, C. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7088 · Cited by 4
The significance of tumor microenvironment for immunotherapy in melanoma and non-melanoma skin cancer
Fujimura, T. (2025) · Immunological Medicine · doi:10.1080/25785826.2025.2550795 · Cited by 3
Successful treatment of localized Merkel cell carcinoma with avelumab in a patient with amyotrophic lateral sclerosis
Arnold, L., Tomsitz, D., Buchillon, R., Leding, J., Senner, S., Frey, S., Janjic, N., French, L. E., & Heinzerling, L. M. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2554566 · Cited by 3
Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden
Dai, M., Sheng, J., Zhang, Q., Wang, J., Fu, Q., & Liang, T. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1118633 · Cited by 3
Evaluation of Chelator-to-Antibody Ratio on Development of 89Zr-iPET Tracer for Imaging of PD-L1 Expression on Tumor
Tsai, S., Farn, S., Lo, W.-L., Yang, F.-Y. O., Kang, Y.-C., Chen, L., Chen, K., Liao, J., Kung, J.-Y., Chen, J.-T., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417132 · Cited by 3
Lower Eyelid Merkel Cell Carcinoma in a Non-Immunocompromised Young Female: A Case Report
Komatsu, Y., Kitaguchi, Y., Kurashige, M., Morimoto, T., & Nishida, K. (2024) · Case Reports in Ophthalmology · doi:10.1159/000536098 · Cited by 3
Development of a Multiplex Immunofluorescence Assay for Tumor Microenvironment Studies of Human and Murine Merkel Cell Carcinoma
Sun, L., Verhaegen, M. E., McGue, J. J., Olivei, A. C., Dlugosz, A. A., Frankel, T. L., & Harms, P. W. (2024) · Laboratory Investigation · doi:10.1016/j.labinv.2024.102128 · Cited by 3
Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinoma
Glutsch, V., Schummer, P., Goebeler, M., Gesierich, A., & Schilling, B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1495004 · Cited by 3
m276-SL-PBD eradicates tumors and instigates long-lasting tumor-free survival in Merkel cell carcinoma preclinical models
Kunika, M. D., Kannan, A., Velasco, G. J., Feng, Y., Seaman, S., Das, B. K., Pham, D., Lambrecht, N. W. G., Zhao, H., Croix, B. S., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112436 · Cited by 3
Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinoma
Oldani, S., Prinzi, N., Morano, F., Cingarlini, S., Giacomo, A. M. D., Niger, M., Prisciandaro, M., Raimondi, A., Randon, G., Pircher, C. C., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2514402 · Cited by 3
Merkel cell carcinoma of the anorectum: a case report and review of the literature
van Wyk, A. C., Moolla, Z., Motala, A. I., Roberts, R., Chotey, N. A., Lakhi, H. I., & Becker, J. C. (2022) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-022-01648-y · Cited by 3
Comorbid immunosuppression in Merkel cell carcinoma: A retrospective database study
Riviere, P. J., Brazel, D., Goshtasbi, K., Kuan, E. C., Gao, L., & Harris, J. P. (2022) · JAAD International · doi:10.1016/j.jdin.2021.09.005 · Cited by 3
Feline papillomavirus-associated Merkel cell carcinoma: a comparative review with human Merkel cell carcinoma
CHAMBERS, J. K., Ito, S., & Uchida, K. (2023) · Journal of Veterinary Medical Science · doi:10.1292/jvms.23-0322 · Cited by 3
First-line Immunotherapy for Metastatic Merkel Cell Carcinoma
Kakish, H. H., Sun, J. X., Ammori, J. B., Hoehn, R. S., & Rothermel, L. D. (2024) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001098 · Cited by 3
Updates in Management of Local-Regionally Advanced Merkel Cell Carcinoma
Frey, A., & Olino, K. L. (2025) · Surgical Clinics of North America · doi:10.1016/j.suc.2024.11.010 · Cited by 3
Immune Checkpoint Inhibitor‐Related Dysautonomia in Merkel Cell Carcinoma: A Case Report
Kuchimanchi, N., Gajula, S., Gaughan, E. M., & Witt, R. G. (2025) · Cancer Reports · doi:10.1002/cnr2.70274 · Cited by 3
Merkel cell carcinoma: Do Australians have a more aggressive variant and a worse outcome?
Veness, M. (2017) · Australasian Journal of Dermatology · doi:10.1111/ajd.12708 · Cited by 3
Das Merkelzellkarzinom: Ätiopathogenese und Management
Heitmann, J., Houben, R., Schrama, D., Goebeler, M., Gesierich, A., & Schilling, B. (2019) · Aktuelle Dermatologie · doi:10.1055/a-0806-9934 · Cited by 3
Immunotherapy in Nonmelanoma Skin Cancer
Bassas, P., Aparicio, G., & Briones, V. G.-P. (2019) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2019.04.002 · Cited by 3
Caring for Patients Treated With Checkpoint Inhibitors for the Treatment of Metastatic Merkel Cell Carcinoma
Rubin, K. M., Hoffner, B., & Bullock, A. C. (2019) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2019.08.003 · Cited by 3
Development of Merkel Cell Carcinoma and Squamous Cell Carcinoma During Treatment With Pembrolizumab for Metastatic Mucosal Melanoma
Hajar, T., Hill, E. E., & Leitenberger, J. J. (2019) · Dermatologic Surgery · doi:10.1097/dss.0000000000002164 · Cited by 3
Prognostic and predictive role of the tumor immune landscape
Haanen, J. B. A. G., & Blank, C. U. (2020) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.20.03255-0 · Cited by 3
BIO-ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF AVELUMAB, AXITINIB AND ITS APPLICATION TO PHARMACOKINETIC STUDIES IN RABBIT PLASMA BY USING LCMS/MS
RAFI, S., & Rambabu, K. (2021) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2021v13i5.42415 · Cited by 3
Immunotherapy in skin cancers - A narrative review
Anjali, V. T., & Kaliyadan, F. (2022) · Journal of Skin and Sexually Transmitted Diseases · doi:10.25259/jsstd_74_2021 · Cited by 3
Dataset for the Reporting of Merkel Cell Carcinoma
BUSAM, K. J., Judge, M. J., Bichakjian, C. K., Coit, D. C., Kutzner, H., Requena, L., Scolyer, R. A., Stefanato, C. M., Wood, B. A., & Walsh, N. M. G. (2022) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001959 · Cited by 3
A Regional Survey on Merkel Cell Carcinoma: A Plea for Uniform Patient Journey Modeling and Diagnostic–Therapeutic Pathway
Roberto, M., Botticelli, A., Caggiati, A., Chiriatti, A., Rocca, C. D., Ferraresi, V., Musicco, F., Pellacani, G., & Marchetti, P. (2022) · Current Oncology · doi:10.3390/curroncol29100570 · Cited by 3
Tumor immunology
Sharif, P. M., Khoshbin, A. P., Nasrollahzadeh, E., Keshavarz‐Fathi, M., & Rezaei, N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818006-8.00003-7 · Cited by 3
Prognostic factors in the primary care of patients with Merkel cell carcinoma: A monocentric cohort study of 108 patients from a tertiary referral centre
Placke, J., Zahn, M. O., Zillikens, H., Krefting, F., Lodde, G. C., Zimmer, L., Livingstone, E., Hadaschik, E. N., Sucker, A., Roesch, A., et al. (2023) · JEADV Clinical Practice · doi:10.1002/jvc2.231 · Cited by 3
A systematic review of Merkel cell carcinoma epidemiology highlights its rising incidence, poor prognosis and data heterogeneity
Mistry, K., & Venables, Z. C. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljad434 · Cited by 3
Avelumab in the Treatment of Advanced Merkel Cell Carcinoma: A Systematic Review
Sharma, A., Shah, K. S., Sharma, A. A., & Yu, S. S. (2024) · Dermatologic Surgery · doi:10.1097/dss.0000000000004107 · Cited by 3
Immune Checkpoint Inhibition in Cancers that Affect the Head and Neck
Parameswaran, J., & Burtness, B. A. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.03.003 · Cited by 3
Immune Checkpoint Inhibitors: Game Changing Cancer Therapy With a Cardiac Cost. What Are the Mechanisms and Unresolved Questions in Cardiotoxicity?
Johnson, C. B., & Ong, M. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.04.010 · Cited by 3
Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2017 MauiDerm Meeting.
LeQuang, J. A. (2017) · PubMed Central · Cited by 3
Multidisciplinary Treatment of Merkel Cell Carcinoma of the Extremities: Outcomes and Factors Associated with Poor Survival in Nodal Disease
Broida, S. E., Chen, X. T., Wahlig, B. D., Moran, S. L., & Houdek, M. T. (2023) · Current Oncology · doi:10.3390/curroncol30070462 · Cited by 3
Updates to Clinical Information on Anticancer Immunotherapy
Choi, E., & Yang, J. W. (2018) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2017.28.1.65 · Cited by 3
Clinical and Epidemiological Characteristics of Merkel Cell Carcinoma in a Series of 38 Patients
Dañino-García, M., Dominguez‐Cruz, J. J., Pérez-Ruiz, C., Conejo‐Mir, J., & Rodríguez, J. (2019) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2019.04.011 · Cited by 3
Comparison of survivor scores for differentiation therapy of cancer to those for checkpoint inhibition: Half full or half empty
Sell, S., & Ilic, Z. (2019) · Tumor Biology · doi:10.1177/1010428319873749 · Cited by 3
Contemporary Topics in Radiation Medicine
Gao, S. J., & Decker, R. H. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.09.008 · Cited by 3
Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response
Hooiveld-Noeken, J. S., Fehrmann, R. S. N., de Vries, E. G. E., & Jalving, M. (2019) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2019.11.002 · Cited by 3
High Precision Ping-Pong Auto-Zeroed Lock-in Fluorescence Photometry Sensor
Lazarjan, V. K., Crochetière, M., Khiarak, M. N., Aarani, S. G., Hosseini, S. N., Gagnon-Turcotte, G., Marquet, P. P., & Gosselin, B. J. (2024) · IEEE Transactions on Biomedical Circuits and Systems · doi:10.1109/tbcas.2024.3388569 · Cited by 2
Poorly Differentiated Neuroendocrine Tumors of the Pancreas: A Comparative Analysis of Primary Versus Secondary Tumors—A Literature Review
Markov, A., Pokhrel, A., & Wang, J. C. C. (2025) · Biomedicines · doi:10.3390/biomedicines13061437 · Cited by 2
Targeting archetypes of viral-driven cancers with immunotherapy: a perspective on immunogenicity within the tumor microenvironment
Lee, K., Kim, S., Zhao, J., & Neo, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1631258 · Cited by 2
Targeting an essential viral oncoprotein with an IL-7-enhanced mRNA vaccine induces durable immunity to Merkel cell carcinoma
Frey, A., Clulo, K., Fei, Y., Dumit, T. C., Scallo, F., Allen, J. W., Chang, E., Perry, C. J., Wirth, L. V., Jacobs, D., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116359 · Cited by 3
Self-citation
Immune Checkpoint Inhibitors in High-grade Gastroenteropancreatic Neuroendocrine Neoplasms
Fazio, N., & Salvia, A. L. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf037 · Cited by 2
Recombinant CALR polarizes and activates macrophages in tumors
Manole, S., & Forbes, N. S. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.201121 · Cited by 2
Avelumab real-world use in advanced Merkel cell carcinoma: a systematic review and non-comparative meta-analysis
Freitag, A., Lan, Z., Moradian, H., Rutherford, M., Kwon, C. S., & Kearney, M. (2026) · Future Oncology · doi:10.1080/14796694.2025.2610172 · Cited by 2
Clinical benefit of adding radiation for immune checkpoint inhibitor-refractory Merkel cell carcinoma: A 27-patient analysis
Alam, R., Menon, A. A., Ch’en, P. Y., Jabbour, A. J., Gooley, T. A., Hippe, D. S., Bhakuni, R., Miller, N., Lachance, K., Park, S. Y., et al. (2026) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2026.01.021 · Cited by 2
Self-citation
Evaluation of Talimogene Laherparepvec for the Treatment of Advanced Nonmelanoma Skin Cancers
Slatton, J., Jiminez, V. S., Beam, J., Rademacher, N., Montgomery, K., Bateni, S., & Broman, K. K. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-19182-3 · Cited by 2
Entering the Age of Specificity in T Cell Immunity
Thomas, P. G. (2026) · Immunological Reviews · doi:10.1111/imr.70184 · Cited by 2
Significant response to Pembrolizumab for metastatic cutaneous squamous cell carcinoma in patient with Netherton syndrome
Tos, S. M., Alqam, B., Giacaman, N., Ibdah, M. G., Gabajah, M. M. M., & Al-Tell, A. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.104323 · Cited by 2
The effect of selinexor on prostaglandin synthesis in virus-positive Merkel cell carcinoma cell lines
Narayanan, D., Bartley, B., Landes, J., Moore, S. A., Kulkarni, V. K., He, Q., Simonette, R. A., Doan, H. Q., Rady, P. L., & Tyring, S. K. (2024) · Archives of Dermatological Research · doi:10.1007/s00403-024-03108-8 · Cited by 2
TO MARKET, TO MARKET—2023: MACROMOLECULAR THERAPEUTICS
Lim, S. A., Agard, N. J., Kelly, R. L., Bell, B. N., Chen, S.-J., Gram, A. M., Moench, I., Pance, K., & Petojevic, T. (2024) · Medicinal chemistry reviews · doi:10.1021/mc-2024-vol59.ch20 · Cited by 2
Merkelzellkarzinom: selten, aber aggressiv
Ludwig‐Peitsch, W., Ruppel, E., & Zahn, A. (2018) · hautnah dermatologie · doi:10.1007/s15012-018-2610-3 · Cited by 2
Manipulation of the Host Immune Response by Small DNA Tumor Viruses
White, E. A., Shanmugasundaram, S., & You, J. (2019) · Current cancer research · doi:10.1007/978-3-030-04155-7_13 · Cited by 2
Case of Merkel cell carcinoma in a patient with pre-existing ILD
Maniar, R., Anderson, M. R., Taback, B., Khan, S. A., McDonnell, D. E., Saqi, A., Niedt, G. W., & Carvajal, R. D. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001672 · Cited by 2
222 Genetic reprogramming of merkel cell carcinoma and melanoma leads to increased MHC-I expression and antitumor immune activation in vitro and in vivo
Luly, K. M., Green, J. J., Tzeng, S. Y., & Sunshine, J. C. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-sitc2021.222 · Cited by 2
Self-citation
Merkel Cell Carcinoma with Gastric Metastasis, a Rare Presentation: Case Report and Literature Review
Durastante, V., Conte, A., Brollo, P. P., Biddau, C., Graziano, M., & Bresadola, V. (2022) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-022-00817-z · Cited by 2
Merkel cell carcinoma in a 38-year-old man: a case report
Liu, Y., Liang, W., Chen, Q., & Wei, Y. (2023) · Anais Brasileiros de Dermatologia · doi:10.1016/j.abd.2022.05.009 · Cited by 2
Longitudinal multi-functional analysis identified responses of T cells, B cells, and monocytes as hallmarks of immunotherapy tolerance in patients with merkel cell carcinoma
Tao, Q., Du, J.-X., Zhang, S., Lin, W., Luo, Y., Liu, Y., Zeng, J., & Chen, X. (2023) · PLoS ONE · doi:10.1371/journal.pone.0293922 · Cited by 2
Where do we stand with immunotherapy for nonmelanoma skin cancers in the curative setting?
Alberti, A., Gurizzan, C., Baggi, A., & Bossi, P. (2023) · Current Opinion in Otolaryngology & Head & Neck Surgery · doi:10.1097/moo.0000000000000945 · Cited by 2
Merkel Cell Carcinoma on the Face: Case Report
Alhaj, S. S., Qaderi, F. A., Ibrahim, T., & Almohammad, M. (2024) · JMIR Dermatology · doi:10.2196/56658 · Cited by 2
Consensus on the clinical diagnosis and treatment of grade 3 pancreatic neuroendocrine tumors
Chen, J., Wu, W., Bai, C., Chi, Y., Huo, L., Jiang, L., Ji, Y., Luo, J., Li, J., Li, J., et al. (2024) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000183 · Cited by 2
Lack of Clinically Significant Relationships of Age or Body Mass Index with Merkel Cell Carcinoma Immunotherapy Outcomes
Alam, R., Fan, X., Hippe, D. S., Tachiki, L. M. L., Gong, E. S., Huynh, E. T., Nghiem, P., & Park, S. Y. (2024) · Cancers · doi:10.3390/cancers16132480 · Cited by 2
Self-citation
Quality of life and patient‐reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body radiation therapy
Hoogland, A. I., Brohl, A. S., Small, B. J., Michael, L., Wuthrick, E. J., Eroglu, Z., Blakaj, D. M., Verschraegen, C. F., Khushalani, N. I., Jim, H., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.7464 · Cited by 2
Lymphocyte Activation Gene 3 Expression, γδ T-Cell/Major Histocompatibility Complex Class I Interactions, and Prognosis in Merkel Cell Carcinoma
Lai, J., Madan, V., Qadri, A., Danilova, L., Yuan, L., Jacobs, V., Ogurtsova, A., Engle, L. L., & Sunshine, J. C. (2024) · Laboratory Investigation · doi:10.1016/j.labinv.2024.102178 · Cited by 2
Self-citation
Facteurs prédictifs et biomarqueurs précoces de réponse aux inhibiteurs de checkpoint immunologiques (anti-PD-1, anti-PD-L1)
Colle, E., André, T., Lebbé, C., & Borg, C. (2016) · ONCOLOGIE · doi:10.1007/s10269-016-2664-y · Cited by 2
PD ‐1 checkpoint blockade is an emerging treatment for Merkel cell carcinoma
Cassler, N. M., & Brownell, I. (2017) · British Journal of Dermatology · doi:10.1111/bjd.14828 · Cited by 2
Immune Checkpoint Inhibition
Sammons, S. L., McNamara, M. A., Salama, A. K. S., & Crawford, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-70253-7_12 · Cited by 2
Poster
(2017) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13300 · Cited by 2
Capital Efficiency for Development Stage Biotech-Based Firms: An IPO Perspective
Ahn, M. J., & Shaygan, A. (2019) · Portland International Conference on Management of Engineering and Technology (PICMET) · doi:10.23919/picmet.2019.8893821 · Cited by 2
MORPHOLOGICAL FEATURES AND MODERN STRATEGIES OF TREATMENT OF MERKEL CELL CARCINOMA
Ermilov, V. V., Zagrebin, V. L., Борисович, Б. В., Markelov, V. V., & Микаилзаде, Г. Ф. (2020) · Journal of Volgograd State Medical University · doi:10.19163/1994-9480-2020-1(73)-3-9 · Cited by 2
Carcinoma de células de Merkel: estudio descriptivo de 11 casos
García‐Zamora, E., Vela-Ganuza, M., Martín‐Alcalde, J., Medrano, R. M., Pinedo, F., & López-Estebaranz, J. L. (2020) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2019.04.014 · Cited by 2
Merkel cell carcinoma in Turkey
Yildiz, F., Demirci, U., Küçükarda, A., Büyüksimsek, M., Sakalar, T., Topcu, T. O., Aslan, F., Tufan, G., Aydin, O., Turna, H., et al. (2020) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_950_19 · Cited by 2
Epidemiology and Retrospective Analysis in Extrapulmonary Neuroendocrine Carcinoma
Sethi, A., Islam, M. K., Moses, R., & Finley, G. G. (2021) · Cureus · doi:10.7759/cureus.12748 · Cited by 2
メルケル細胞ポリオーマウイルス
永瀬, 浩. (2022) · Skin Cancer · doi:10.5227/skincancer.37.79 · Cited by 2
Neuroendocrine Tumors and Immune System
Modica, R., Liccardi, A., Benevento, E., Minotta, R., Cannavale, G., & Colao, A. A. L. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2023_147 · Cited by 2
Multiplex Immunohistochemistry Staining for Paraffin-embedded Lung Cancer Tissue
Yang, Y., Huang, H., Li, L., & Yang, Y. (2023) · Journal of Visualized Experiments · doi:10.3791/65850 · Cited by 2
Durable response to programmed death-1 (PD-1) blockade in a metastatic gastric cancer patient with mismatch repair deficiency and microsatellite instability
Wu, T., Hsiue, E. H.-C., Yuan, C., Tseng, L., Lin, C., & Yeh, K. (2016) · Journal of Cancer Research and Practice · doi:10.1016/j.jcrpr.2016.11.001 · Cited by 2
Radiation Therapy in Merkel Cell Carcinoma
Veness, M. (2018) · Springer eBooks · doi:10.1007/978-3-319-52619-5_16-1 · Cited by 2
Merkel cell carcinoma: long-term follow-up of a single institution series and clinical outcomes by immunological status
Dasanu, C. A., Rosario, M. D., Codreanu, I., Lu, Y., Farrell, S., Hyams, D. M., & Plaxe, S. C. (2019) · Dermatology Online Journal · doi:10.5070/d3252042886 · Cited by 2
A case of merkel leptomeningeal evolution after complete remission upon anti–PD-1 treatment
Godeau, M., Pagès, C., Severino‐Freire, M., Guinard, E., Tauber, M., Ciron, D. L., Lamant, L., Evrard, S., Riffaud, L., Sibaud, V., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.03.009 · Cited by 2
Cutaneous Scapular Lesion in an Elderly Woman
Brighi, N., Lamberti, G., & Campana, D. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1754 · Cited by 2
[Clinical Diagnosis and Treatment Recommendations for Ocular Toxicities of Target Therapy and Immune Checkpoint Inhibitor Therapy].
Liu, X., Wang, Z., Zhao, C., Wang, H., Guo, X., Zhou, J., Duan, L., Si, X., Zhang, L., Li, Y., et al. (2019) · PubMed Central · doi:10.3779/j.issn.1009-3419.2019.10.09 · Cited by 2
Merkel-Zell-Karzinom bei chronisch lymphatischer Leukämie
Dücker, P., Hüning, S., Rohde, S., Lorenzen, J., & Nashan, D. (2020) · Der Hautarzt · doi:10.1007/s00105-020-04599-y · Cited by 2
An Aggressive Presentation of Merkel Cell Carcinoma: A Case Report
Zemni, I., Sabrine, H., Saadallah, F., Ali, A. M., Charfi, L., Chargui, R., & Rahal, K. (2020) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709620963714 · Cited by 2
Bone Scintigraphy in Pembrolizumab-Induced Inflammatory Arthritis
Imai, M., Kosaka, Y., Masato, T., Mori, K., & Maruno, H. (2020) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003332 · Cited by 2
The clinical and prognostic significance of CMTM6/PD-L1 in oncology
Yaseen, M. M., Abuharfeil, N. M., & Darmani, H. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02811-0 · Cited by 2
Avelumab
Dudzisz‐Śledź, M., Teterycz, P., Rutkowski, P. L., & Becker, J. C. (2021) · Springer eBooks · doi:10.1007/978-3-030-64009-5_15 · Cited by 2

Authors: Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., Friedlander, P. A., Kluger, H. M., Kohrt, H. E., Lundgren, L., Margolin, K., Mitchell, A., Olencki, T., Pardoll, D. M., Reddy, S. A., Shantha, E. M., Sharfman, W. H., Sharon, E., Shemanski, L. R., Shinohara, M. M., Sunshine, J. C., Taube, J. M., Thompson, J. A., Townson, S. M., Yearley, J. H., Topalian, S. L., & Cheever, M. A.
Affiliations: Johns Hopkins University (US)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Mount Sinai Hospital (US)
ORCID: Nghiem, Paul T.
Bhatia, Shailender
Lipson, Evan J.
Kudchadkar, Ragini R.
Miller, Natalie J.
Berry, Sneha
Chartash, Elliot K.
Daud, Adil
Fling, Steven P.
Friedlander, Philip A.
Kluger, Harriet M.
Lundgren, Lisa
Margolin, Kim
Pardoll, Drew M.
Reddy, Sunil A.
Sharfman, William H.
Sharon, Elad
Shinohara, Michi M.
Sunshine, Joel C.
Taube, Janis M.
Thompson, John A.
Topalian, Suzanne L.
Cheever, Martin A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2016-06-30
Volume: 374
Issue: 26
Pages: 2542-2552
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1603702
PMC: PMC4927341
OpenAlex: W2339890238
Cited by: 1,258
References: 42
Citations by year: 2026: 40 · 2025: 68 · 2024: 76 · 2023: 86 · 2022: 104 · 2021: 141 · 2020: 166 · 2019: 172 · 2018: 187 · 2017: 174 · 2016: 40
FWCI: 103.02
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Institutes of Health (5u01ca154967-06)
National Cancer Institute (U01-CA-154967, R01CA162522, 1U01CA154967, K24CA139052, UM1CA154967, R01CA142779, P30CA006973)
National Institute of General Medical Sciences (T32GM007266)
Topics: Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Dermatology › Nonmelanoma Skin Cancer Studies
Keywords: Merkel cell carcinoma, pembrolizumab, anti-PD-1 therapy, immune checkpoint inhibitors, Merkel cell polyomavirus, PD-L1 expression, first-line therapy, objective response rate, progression-free survival, cutaneous squamous cell carcinoma, immune-related adverse events, treatment-related adverse events, treatment duration, drug safety and efficacy
MeSH terms: Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Neoplasm Staging, Recurrence, Skin Neoplasms, Carcinoma, Merkel Cell, Disease-Free Survival, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks